Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631806 | 0.81 | ALDH1A1 (0.52) | GRM4SYKKDM4EALDH1A1NPC1 | |
| SCHEMBL4799379 | 0.81 | GRM4 (0.48) | GRM4GRM8GRM7KDM4EALDH1A1 | |
| SCHEMBL28443118 | 0.81 | GRM4 (0.48) | GRM4GRM8GRM7KDM4EALDH1A1 | |
| SCHEMBL24741603 | 0.81 | MEN1 (0.54) | GRM4SYKKDM4ENPC1MAP4K4 | |
| SCHEMBL30108336 | 0.81 | MEN1 (0.54) | GRM4SYKKDM4ENPC1MAP4K4 | |
| SCHEMBL4796549 | 0.81 | KDM4E (0.47) | GRM4SYKKDM4EALDH1A1NPC1 | |
| SCHEMBL15902913 | 0.80 | ALDH1A1 (0.44) | GRM4SYKKDM4EALDH1A1NPC1 | |
| SCHEMBL4796659 | 0.79 | KDM4E (0.49) | SYKKDM4EALDH1A1NPC1KMT2A | |
| SCHEMBL4795125 | 0.79 | GRM4 (0.50) | GRM4SYKKDM4EKMT2AMEN1 | |
| SCHEMBL28440382 | 0.79 | GRM4 (0.47) | GRM4GRM8GRM7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | claimed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1292591-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | GRM4 3324/4885SYK 4340/4885GRM8 4221/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | GRM4 4041/4885SYK 3945/4885GRM8 4421/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | GRM4 1914/4885SYK 146/4885GRM8 2029/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | GRM4 1402/4885SYK 358/4885GRM8 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.